Knight Therapeutics (GUD) Insider Trading & Ownership C$5.21 -0.01 (-0.19%) (As of 05:28 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades Knight Therapeutics (TSE:GUD) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage45.62%Number OfInsiders Buying(Last 12 Months)3Amount OfInsider Buying(Last 12 Months)C$2.47 MNumber OfInsiders Selling(Last 12 Months)3Amount OfInsider Selling(Last 12 Months)C$3.18 M Get GUD Insider Trade Alerts Want to know when executives and insiders are buying or selling Knight Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address GUD Insider Buying and Selling by Quarter Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Knight Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/12/2024Sime ArmoyanInsiderBuy90,300C$5.13C$463,672.4411/11/2024Samira SakhiaDirectorBuy20,000C$5.15C$103,000.009/16/2024Sime ArmoyanInsiderSell300,000C$6.13C$1,839,000.008/19/2024Amal KhouriSenior OfficerSell5,000C$5.78C$28,919.008/15/2024Amal KhouriSenior OfficerSell500C$5.75C$2,875.008/13/2024Amal KhouriSenior OfficerSell5,000C$5.75C$28,750.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 7/11/2024Amal KhouriSenior OfficerSell10,000C$5.70C$57,000.007/3/2024Amal KhouriSenior OfficerSell10,000C$5.72C$57,200.006/10/2024Amal KhouriSenior OfficerSell20,000C$5.80C$116,022.006/5/2024Jonathan Ross GoodmanDirectorBuy5,000C$5.80C$29,000.005/29/2024Robert Nathaniel LandeDirectorSell15,000C$5.91C$88,600.505/23/2024Robert Nathaniel LandeDirectorSell20,000C$5.94C$118,710.005/7/2024Sime ArmoyanInsiderSell15,000C$5.95C$89,250.004/11/2024Sime ArmoyanInsiderSell10,900C$5.95C$64,855.004/1/2024Sime ArmoyanInsiderBuy6,200C$5.25C$32,550.003/25/2024Sime ArmoyanInsiderBuy351,000C$5.25C$1,842,750.001/22/2024Sime ArmoyanInsiderSell28,200C$5.75C$162,150.001/19/2024Sime ArmoyanInsiderSell91,000C$5.75C$523,250.00 (Data available from 1/1/2013 forward) GUD Insider Trading Activity - Frequently Asked Questions Who is on Knight Therapeutics's Insider Roster? The list of insiders at Knight Therapeutics includes Amal Khouri, Janice Jean Murray, Jonathan Ross Goodman, Long Zone Holdings Inc. , Robert Nathaniel Lande, Samira Sakhia, and Sime Armoyan. Learn more on insiders at GUD. What percentage of Knight Therapeutics stock is owned by insiders? 45.62% of Knight Therapeutics stock is owned by insiders. Learn more on GUD's insider holdings. Which Knight Therapeutics insiders have been buying company stock? The following insiders have purchased GUD shares in the last 24 months: Jonathan Ross Goodman (C$29,000.00), Samira Sakhia (C$103,000.00), and Sime Armoyan (C$2,459,495.04). How much insider buying is happening at Knight Therapeutics? Insiders have purchased a total of 500,000 GUD shares in the last 24 months for a total of C$2,591,495.04 bought. Which Knight Therapeutics insiders have been selling company stock? The following insiders have sold GUD shares in the last 24 months: Amal Khouri (C$290,766.00), Robert Nathaniel Lande (C$207,310.50), and Sime Armoyan (C$2,678,505.00). How much insider selling is happening at Knight Therapeutics? Insiders have sold a total of 530,600 Knight Therapeutics shares in the last 24 months for a total of C$3,176,581.50 sold. Knight Therapeutics Key ExecutivesMr. Jonathan Ross Goodman B.A. (Age 55)L.L.B., M.B.A., Executive Chairman Compensation: $250.94kMs. Samira Sakhia BCom (Age 56)CA, CPA, MBA, President, CEO & Director Compensation: $674.28kMr. Arvind UtchanahChief Financial OfficerMs. Amal Khouri B.Sc.M.B.A., Chief Business OfficerMr. Jeff MartensGlobal Vice President of CommercialMr. Stephani SaverioVice President of Business DevelopmentMr. Leopoldo BosanoVice-President of Manufacturing & OperationsMs. Monica PercarioGlobal Vice President of Scientific AffairsMr. Henrique DiasGlobal Director of MarketingMs. Susan Caroline EmblemGlobal Vice President of Human Resources More Insider Trading Tools from MarketBeat Related Companies WEED Insider Trades ACB Insider Trades OGI Insider Trades RX Insider Trades CRDL Insider Trades HLS Insider Trades SUGR Insider Trades MDP Insider Trades DB Insider Trades WLLW Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (TSE:GUD) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored“The Last Retirement Stock You’ll Ever Need”We've just released a critical trade alert about a groundbreaking AI investment opportunity. So, I wanted t...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Knight Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.